<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292444</url>
  </required_header>
  <id_info>
    <org_study_id>RAGE</org_study_id>
    <nct_id>NCT04292444</nct_id>
  </id_info>
  <brief_title>Effects of Oxytocin on Cognitive and Reactive Fear</brief_title>
  <acronym>RAGE</acronym>
  <official_title>Disentangling Effects of Oxytocin on Cognitive and Reactive Fear and the Moderating Role of the Receptor for Advanced Glycation End-products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study examines the (sub)regional specificity of anxiolytic oxytocin (OXT) effects on
      emotional face processing and reactive and cognitive fear. Preliminary data indicate that the
      Receptor for Advanced Glycation End Products (RAGE) may regulate oxytocin transport into the
      brain. Thus, the study aims to replicate previous observations of oxytocin effects on the
      processing of fearful faces in the centro-medial amygdala and to assess whether a RAGE
      polymorphism (-374 T/A: rs1800624; TT vs. TA/AA), that has been shown to alter
      transcriptional activity, modulates anxiolytic OXT effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      So far, no study examined selective oxytocin (OXT) effects on reactive (midbrain
      periaqueductal gray (PAG), central amygdala (CeA), hypothalamus, and the midcingulate cortex
      (MCC)) and cognitive fear (ventromedial prefrontal cortex (vmPFC), posterior cingulate cortex
      (PCC), hippocampus, and basolateral amygdala) and the reward system (striatum) with high
      spatial resolution. Previous studies showed that 7T functional magnetic resonance imaging
      (fMRI) results in a higher spatial resolution and specificity than 3T MRI in these brain
      regions and would thus allow for a more detailed characterization of the neural effects.

      To disentangle (sub)region-specific effects of OXT on task-related activations of the
      cingulate structures, the amygdala, the striatum, PAG and VMPFC, the investigators plan to
      acquire ultra-high field 7T fMRI data from healthy male participants while they perform (i)
      an emotional face matching task and (ii) a flight initiation distance (FID) task involving
      fast- or slow-attacking virtual predators that elicit distinct activations in the reactive
      and cognitive fear circuits. Furthermore, participants will be pre-stratified depending on
      RAGE polymorphisms to elucidate possible RAGE-related differential OXT effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study is designed as a double-blind, within-subject, placebo-controlled, non-clinical trial and will involve healthy male participants (n = 60), who will be scanned twice in a randomized order after a single dose of intranasal OXT (24 IU) or placebo. Furthermore participants will be pre-stratified based on a RAGE polymorphism (-374 T/A: rs1800624; n = 30 with TT alleles and n = 30 with TA/AA alleles).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neural substrates of emotion processing, measured via blood-oxygen-level dependent (BOLD) signal in the amygdala and striatum</measure>
    <time_frame>30 minutes after nasal spray administration</time_frame>
    <description>Functional magnetic resonance imaging will be performed to measure the BOLD signal in response to emotional face stimuli. The investigators specifically plan to investigate neural responses to emotional faces in amygdala and striatal subregions. The BOLD signal in response to fearful faces relative to neutral faces and happy faces relative to neutral will be compared between the oxytocin and placebo sessions. To examine effects of the Receptor for Advanced Glycation End Products (RAGE), analyses of variance (ANOVAs) with the between subjects factor RAGE polymorphism (-374 T/A: rs1800624; TT vs. TA/AA) will be conducted on the second level. For analyses of fMRI data, default procedures of the software SPM12 will be adapted for ultra-high-field imaging. The family-wise error rate will be used to correct p-values for multiple comparisons and p &lt; .05 will be considered significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neural responses in the flight initiation distance (FID) task</measure>
    <time_frame>45 minutes after nasal spray administration</time_frame>
    <description>Functional magnetic resonance imaging will be performed to measure the blood-oxygen-level dependent (BOLD) signal in a flight initiation distance (FID) task, involving fast-, medium- and slow-attacking virtual predators that elicit distinct activations in the reactive and cognitive fear circuits. BOLD signals to different predator velocities will be analyzed. Analyses will focus on regions-of-interest associated with the processing of cognitive fear (vmPFC, PCC, hippocampus, and basolateral amygdala) and reactive fear (midbrain PAG, central amygdala, hypothalamus, and the MCC) and the reward system (striatum). To examine effects of the Receptor for Advanced Glycation End Products (RAGE), ANOVAs with the between-subject factor RAGE polymorphism (-374 T/A: rs1800624; TT vs. TA/AA) will be conducted on the 2nd level. For the fMRI data, default procedures of the software SPM12 will be adapted for ultra-high-field imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flight distance and difficulty ratings in the flight initiation distance (FID) task</measure>
    <time_frame>45 minutes after nasal spray administration</time_frame>
    <description>Behavioral data of the FID task (flight distance and difficulty ratings ) will be analyzed using mixed ANOVAs in the software SPSS with treatment (oxytocin vs. placebo) as within-subject factor and RAGE polymorphism (TT vs. TA/AA) as between-subject factor. Post-hoc t-tests will be Bonferroni-corrected. Behavioral data will be correlated with fMRI data of the FID task.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxytocin concentration in blood plasma</measure>
    <time_frame>10 minutes before nasal spray administration and 75 minutes after nasal spray administration</time_frame>
    <description>Blood samples will be collected before and after the nasal spray administration to assess changes in oxytocin concentrations. Oxytocin concentrations will be analyzed using mixed ANOVAs in SPSS with time (pre vs. post) and treatment (oxytocin vs. placebo) as within-subject factors and RAGE polymorphism (TT vs. TA/AA) as between-subject factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of receptor for advanced glycation endproducts (extracellular domain) in blood plasma</measure>
    <time_frame>10 minutes before nasal spray administration</time_frame>
    <description>Blood samples will be collected before the nasal spray administration to assess the RAGE (extracellular domain) concentration in blood plasma.
RAGE concentrations will be compared between RAGE polymorphisms (TT vs. TA/AA) with independent t-tests. Furthermore, the investigators plan to examine if the RAGE concentration moderates the effects of oxytocin on primary and secondary outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Oxytocin</condition>
  <arm_group>
    <arm_group_label>RAGE polymorphism (TT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TT) will be selected and scanned twice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAGE polymorphism (TA/AA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TA/AA) will be selected and scanned twice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.</description>
    <arm_group_label>RAGE polymorphism (TA/AA)</arm_group_label>
    <arm_group_label>RAGE polymorphism (TT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).</description>
    <arm_group_label>RAGE polymorphism (TA/AA)</arm_group_label>
    <arm_group_label>RAGE polymorphism (TT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RAGE polymorphism (-374 T/A: rs1800624; TT vs. TA/AA)

          -  healthy male volunteers

          -  right handed

        Exclusion Criteria:

          -  current psychiatric illness

          -  current psychiatric medication or psychotherapy

          -  MRI contraindication (e.g. metal in body, claustrophobia)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rene Hurlemann, MSc, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oldenburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk Scheele, PhD</last_name>
    <phone>+49 (0)228 287</phone>
    <phone_ext>11151</phone_ext>
    <email>Dirk.Scheele@ukbonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie J Coenjaerts, MSc</last_name>
    <phone>+49 (0)228 287</phone>
    <phone_ext>19704</phone_ext>
    <email>Marie.Coenjaerts@ukbonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry and Medical Psychology</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Scheele, PhD</last_name>
      <email>Dirk.Scheele@ukbonn.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://renehurlemann.squarespace.com/welcome/</url>
    <description>Neuromodulation of Emotion (NEMO) Research Group</description>
  </link>
  <reference>
    <citation>Hahn A, Kranz GS, Seidel EM, Sladky R, Kraus C, Küblböck M, Pfabigan DM, Hummer A, Grahl A, Ganger S, Windischberger C, Lamm C, Lanzenberger R. Comparing neural response to painful electrical stimulation with functional MRI at 3 and 7 T. Neuroimage. 2013 Nov 15;82:336-43. doi: 10.1016/j.neuroimage.2013.06.010. Epub 2013 Jun 12.</citation>
    <PMID>23769917</PMID>
  </reference>
  <reference>
    <citation>Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes. 2001 Jun;50(6):1505-11.</citation>
    <PMID>11375354</PMID>
  </reference>
  <reference>
    <citation>Qi S, Hassabis D, Sun J, Guo F, Daw N, Mobbs D. How cognitive and reactive fear circuits optimize escape decisions in humans. Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3186-3191. doi: 10.1073/pnas.1712314115. Epub 2018 Mar 5.</citation>
    <PMID>29507207</PMID>
  </reference>
  <reference>
    <citation>Yamamoto Y, Liang M, Munesue S, Deguchi K, Harashima A, Furuhara K, Yuhi T, Zhong J, Akther S, Goto H, Eguchi Y, Kitao Y, Hori O, Shiraishi Y, Ozaki N, Shimizu Y, Kamide T, Yoshikawa A, Hayashi Y, Nakada M, Lopatina O, Gerasimenko M, Komleva Y, Malinovskaya N, Salmina AB, Asano M, Nishimori K, Shoelson SE, Yamamoto H, Higashida H. Vascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice. Commun Biol. 2019 Feb 25;2:76. doi: 10.1038/s42003-019-0325-6. eCollection 2019.</citation>
    <PMID>30820471</PMID>
  </reference>
  <reference>
    <citation>Hariri AR, Tessitore A, Mattay VS, Fera F, Weinberger DR. The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage. 2002 Sep;17(1):317-23.</citation>
    <PMID>12482086</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oldenburg</investigator_affiliation>
    <investigator_full_name>Rene Hurlemann</investigator_full_name>
    <investigator_title>Professor for Psychiatry</investigator_title>
  </responsible_party>
  <keyword>fMRI</keyword>
  <keyword>receptor for advanced glycation end-products (RAGE)</keyword>
  <keyword>fear</keyword>
  <keyword>7T MRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

